IL141965A0 - Non-endogenous, constitutively activated human g protein-coupled receptors - Google Patents
Non-endogenous, constitutively activated human g protein-coupled receptorsInfo
- Publication number
- IL141965A0 IL141965A0 IL14196599A IL14196599A IL141965A0 IL 141965 A0 IL141965 A0 IL 141965A0 IL 14196599 A IL14196599 A IL 14196599A IL 14196599 A IL14196599 A IL 14196599A IL 141965 A0 IL141965 A0 IL 141965A0
- Authority
- IL
- Israel
- Prior art keywords
- endogenous
- sub
- sup
- codon
- gpcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein are constitutively activated, non-endogenous versions of endogenous human G protein-coupled receptors comprising (a) the following amino acid sequence region (C-terminus to N-terminus orientation) and/or (b) the following nucleic acid sequence region (3' to 5' orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR: (a) P<SUP>1 </SUP>AA<SUB>15</SUB>X and/or (b) p<SUP>codon </SUP>(AA-codon)<SUB>15 </SUB>X<SUB>codon</SUB>, respectively. In a most preferred embodiment, P<SUP>1 </SUP>and P<SUP>codon </SUP>are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively, located within TM6 of the non-endogenous GPCR; AA<SUB>15 </SUB>and (AA-codon)<SUB>15 </SUB>are 15 endogenous amino acid residues and 15 codons encoding endogenous amino acid residues, respectively; and X and X<SUB>codon </SUB>are non-endogenous lysine and a non-endogenous nucleic acid encoding region encoding lysine, respectively, located within IC3 of the non-endogenous GPCR. Because it is most preferred that the non-endogenous human GPCRs which incorporate these mutations are incorporated into mammalian cells and utilized for the screening of candidate compounds, the non-endogenous human GPCR incorporating the mutation need not be purified and isolated per se (i.e., these are incorporated within the cellular membrane of a mammalian cell), although such purified and isolated non-endogenous human GPCRs are well within the purview of this disclosure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/170,496 US6555339B1 (en) | 1997-04-14 | 1998-10-13 | Non-endogenous, constitutively activated human protein-coupled receptors |
PCT/US1999/023938 WO2000022129A1 (en) | 1998-10-13 | 1999-10-12 | Non-endogenous, constitutively activated human g protein-coupled receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL141965A0 true IL141965A0 (en) | 2002-03-10 |
Family
ID=22620080
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14196599A IL141965A0 (en) | 1998-10-13 | 1999-10-12 | Non-endogenous, constitutively activated human g protein-coupled receptors |
IL141965A IL141965A (en) | 1998-10-13 | 2001-03-12 | Non-endogenous, constitutively activated human g protein-coupled receptors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL141965A IL141965A (en) | 1998-10-13 | 2001-03-12 | Non-endogenous, constitutively activated human g protein-coupled receptors |
Country Status (15)
Country | Link |
---|---|
US (2) | US6555339B1 (en) |
EP (1) | EP1121431B9 (en) |
JP (2) | JP4672866B2 (en) |
KR (1) | KR100598752B1 (en) |
CN (1) | CN1329511C (en) |
AT (1) | ATE318311T1 (en) |
AU (5) | AU769987B2 (en) |
CA (1) | CA2342314A1 (en) |
DE (3) | DE69929993D1 (en) |
DK (1) | DK1121431T5 (en) |
ES (1) | ES2163384T3 (en) |
HK (1) | HK1038040A1 (en) |
IL (2) | IL141965A0 (en) |
NZ (1) | NZ510331A (en) |
WO (2) | WO2000022129A1 (en) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
USRE42190E1 (en) | 1998-11-20 | 2011-03-01 | Arena Pharmaceuticals, Inc. | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors |
US7816492B2 (en) * | 1998-11-20 | 2010-10-19 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors |
US20030017528A1 (en) | 1998-11-20 | 2003-01-23 | Ruoping Chen | Human orphan G protein-coupled receptors |
KR100963367B1 (en) * | 1998-11-20 | 2010-06-14 | 아레나 파마슈티칼스, 인크. | Human Orphan G Protein-Coupled Receptors |
GB9903767D0 (en) * | 1999-02-18 | 1999-04-14 | Univ Glasgow | Receptor assay |
WO2001009383A2 (en) * | 1999-07-30 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders |
JP4768946B2 (en) * | 1999-11-17 | 2011-09-07 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Endogenous and non-endogenous forms of the human G protein coupled receptor |
EP1240199A2 (en) * | 1999-12-10 | 2002-09-18 | AstraZeneca AB | Method for screening of appetite control agents |
JP2003517008A (en) * | 1999-12-17 | 2003-05-20 | アストラゼネカ アクチボラグ | New compound |
WO2001061359A2 (en) * | 2000-02-18 | 2001-08-23 | Glaxo Group Limited | Identification of modulators of gpr41 or gpr42 activity |
GB0003898D0 (en) * | 2000-02-18 | 2000-04-05 | Glaxo Group Ltd | Assay |
GB0003902D0 (en) * | 2000-02-18 | 2000-04-05 | Glaxo Group Ltd | Assay |
AU2001241778A1 (en) * | 2000-02-29 | 2001-09-12 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
EP1149907A1 (en) * | 2000-04-26 | 2001-10-31 | Aventis Pharma Deutschland GmbH | EDG8 receptor, its preparation and use |
AU2001270489B2 (en) * | 2000-04-26 | 2007-03-15 | Sanofi-Aventis Deutschland Gmbh | EDG8 receptor, its preparation and use |
JP2003531637A (en) * | 2000-05-03 | 2003-10-28 | アストラゼネカ アクチボラグ | Method |
US20040029793A1 (en) * | 2000-06-15 | 2004-02-12 | Takeo Moriya | Novel g protein-coupled receptor protein and dna thereof |
EP1297130A2 (en) * | 2000-06-16 | 2003-04-02 | Incyte Genomics, Inc. | G-protein coupled receptors |
WO2001098494A1 (en) * | 2000-06-21 | 2001-12-27 | Takeda Chemical Industries, Ltd | Ligand to gpr8 and dna thereof |
US20040086940A1 (en) * | 2000-07-04 | 2004-05-06 | Sachio Shibata | Novel g protein-coupled receptor protein and dna thereof |
AU2002212140A1 (en) * | 2000-08-18 | 2002-02-25 | Novartis Ag | Inflammation related g-protein coupled receptor |
AU2001286945A1 (en) * | 2000-08-30 | 2002-03-13 | John Hopkins University School Of Medicine | Identification of activated receptors and ion channels |
WO2001027632A2 (en) * | 2000-10-02 | 2001-04-19 | Biofocus Discovery Limited | Cellular receptor mutations predicted by multiple-sequence-allignment |
EP1344823A4 (en) * | 2000-11-30 | 2005-03-16 | Takeda Chemical Industries Ltd | Novel g protein-coupled receptor proteins and dnas thereof |
GB0031527D0 (en) * | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
US7241579B2 (en) | 2000-12-22 | 2007-07-10 | Smithkline Beecham Corporation | Method of screening for GPR40 ligands |
CN1516706A (en) * | 2001-02-26 | 2004-07-28 | 阿伦纳药品公司 | Endogenous and non-endogenous versions of human G protein-coupled receptors |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
US6919176B2 (en) * | 2001-05-07 | 2005-07-19 | Amgen Inc. | Polypeptides and nucleic acids associated with cancer |
DE60222124T2 (en) | 2001-05-15 | 2008-05-29 | Takeda Pharmaceutical Co. Ltd. | SCREENING PROCESS |
US20020177190A1 (en) * | 2001-05-24 | 2002-11-28 | Yanbin Liang | Recombinant simian GPR3 receptor |
AU2002310326A1 (en) * | 2001-06-05 | 2002-12-23 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1 |
JP2003018992A (en) * | 2001-06-28 | 2003-01-21 | Inst Of Physical & Chemical Res | Pael receptor, pael receptor expression cell and animal, amd method for screening drug for parkinson disease |
WO2003006504A2 (en) * | 2001-07-13 | 2003-01-23 | Akzo Nobel N.V. | Allelic variants of gpr50 |
US20030109044A1 (en) * | 2001-10-16 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Methods of using 279, a human G protein-coupled protein receptor |
EP1450666A4 (en) * | 2001-11-05 | 2008-11-12 | Millennium Pharm Inc | Methods and compositions to treat cardiovascular disease using 139,258,1261,1486,2398,2414,7660,8587,10183,10550,12680,17921,32248,60489 or 93804 |
US6902902B2 (en) | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
CA2471504C (en) | 2002-01-07 | 2014-05-20 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr43 and uses thereof |
EP1336655A1 (en) * | 2002-01-12 | 2003-08-20 | Aventis Pharma Deutschland GmbH | Method of identifying protein CAMS (constitutively active mutants) |
WO2003062396A2 (en) * | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Non-endogenous versions of human g protein-coupled receptor: fshr |
WO2003066077A2 (en) * | 2002-02-06 | 2003-08-14 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
ATE466030T1 (en) | 2002-02-14 | 2010-05-15 | Takeda Pharmaceutical | NEW SCREENING PROCESS |
WO2003078602A2 (en) * | 2002-03-15 | 2003-09-25 | Arena Pharmaceuticals, Inc. | Methods of expressing non-endogenous g protein coupled receptors in cells |
WO2003104381A2 (en) * | 2002-06-08 | 2003-12-18 | Astrazeneca Ab | Methods |
CN100473662C (en) * | 2002-08-01 | 2009-04-01 | 阿瑞那制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
AU2003250165A1 (en) * | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19) |
WO2004015426A1 (en) * | 2002-08-06 | 2004-02-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
US20060239999A1 (en) * | 2002-08-22 | 2006-10-26 | Mayumi Saki | Preventive and/or therapeutic drugs for asthma |
AU2003276106A1 (en) * | 2002-10-24 | 2004-05-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
CN101134757A (en) | 2002-11-06 | 2008-03-05 | 安姆根有限公司 | Fused heterocyclic compounds |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
AU2003297644A1 (en) * | 2002-12-04 | 2004-06-23 | Synaptic Pharmaceutical Corporation | Uses of the snorf55 receptor |
US20040157253A1 (en) * | 2003-02-07 | 2004-08-12 | Millennium Pharmaceuticals, Inc. | Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders |
EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
US7427487B2 (en) * | 2003-03-18 | 2008-09-23 | Arena Pharmaceuticals, Inc. | Constitutively active CXCR3 G protein-coupled chemokine receptor and modulators thereof for the treatment of inflammatory disorders |
WO2004093912A1 (en) * | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | Preventive and/or therapeutic agent for neutrophil inflammation disease |
WO2004099419A2 (en) * | 2003-04-30 | 2004-11-18 | Arena Pharmaceuticals, Inc. | Methods and compositions for identifying modulators of g protein-coupled receptors |
US7405053B2 (en) * | 2003-05-20 | 2008-07-29 | The University Court Of The University Of Glasgow | Materials and methods relating to G-protein coupled receptor oligomers |
US7625696B2 (en) * | 2003-09-11 | 2009-12-01 | Takeda Pharmaceutical Company Limited | Screening method |
CA2544733A1 (en) * | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
US20070276024A1 (en) * | 2003-10-09 | 2007-11-29 | Inverseon , Inc. | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists |
WO2005040829A2 (en) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17) |
WO2005040211A2 (en) * | 2003-10-23 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1) |
WO2005040825A2 (en) * | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20) |
WO2005040828A2 (en) * | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
PT1713501E (en) * | 2004-01-29 | 2008-04-30 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of gpr49 |
CA2556757C (en) | 2004-02-20 | 2011-05-03 | Aventis Pharmaceuticals Inc. | Oxydecahydronaphthalene modulators of hm74 |
WO2005101005A1 (en) * | 2004-04-15 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32) |
US7833722B2 (en) * | 2004-04-27 | 2010-11-16 | Takeda Pharmaceutical Company Limited | Ligands for G protein-coupled receptor protein and use thereof |
BRPI0510883B8 (en) | 2004-06-01 | 2021-05-25 | Genentech Inc | drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
KR101270829B1 (en) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | Cystein engineered antibodies and conjugates |
US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
GB0508988D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
US8429755B2 (en) | 2005-05-26 | 2013-04-23 | Sandisk Technologies Inc. | System and method for receiving digital content |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP1934346A1 (en) * | 2005-10-14 | 2008-06-25 | Arena Pharmaceuticals, Inc. | Gpr22 and methods relating thereto |
CN101304654A (en) | 2005-11-10 | 2008-11-12 | 艾尼纳制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto |
GB2447786C (en) | 2007-03-22 | 2011-11-09 | Heptares Therapeutics Ltd | Mutant G-protein coupled receptor proteins and methods for selecting them |
GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
WO2010091692A2 (en) * | 2009-04-30 | 2010-08-19 | H. Lundbeck A/S | Constitutively active mutants and uses thereof |
GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JP5804341B2 (en) * | 2010-08-06 | 2015-11-04 | 国立大学法人山口大学 | Method for determining estrogen-related diseases |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
JP5987053B2 (en) | 2011-05-12 | 2016-09-06 | ジェネンテック, インコーポレイテッド | Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides |
AU2012322607B2 (en) | 2011-10-14 | 2017-02-16 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
EP2906298B1 (en) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
PT2906296T (en) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
ES2680153T3 (en) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Anti-PSMA-pyrrolobenzodiazepine antibody conjugates |
ME03486B (en) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA2887899C (en) | 2012-10-12 | 2020-03-31 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
LT2906253T (en) | 2012-10-12 | 2018-10-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
EA031585B1 (en) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
AR096287A1 (en) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | PIRROLOBENZODIACEPINS AND CONJUGATES |
CN105209077B (en) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and its conjugate |
CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
MX2016001021A (en) | 2013-07-25 | 2016-08-03 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides. |
KR20160031551A (en) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | Cyclic polypeptides for the treatment of heart failure |
US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
BR112016012410A2 (en) | 2013-12-16 | 2017-09-26 | Genentech Inc | drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition |
MX2016007578A (en) | 2013-12-16 | 2016-10-03 | Genentech Inc | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment. |
MX2016007826A (en) | 2013-12-16 | 2017-03-31 | Genentech Inc | Peptidomimetic compounds and antibody-drug conjugates thereof. |
CA2945706C (en) * | 2014-04-25 | 2023-10-24 | Libramen Naturals Inc. | G-protein coupled receptor 22 transformed cell lines and uses therefor |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN107108724A (en) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | Cysteine engineered antibody and conjugate |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20200164068A1 (en) | 2016-02-16 | 2020-05-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of tumor immune resistance for the treatment of cancer |
WO2017140793A1 (en) | 2016-02-16 | 2017-08-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of ccr9 for treating tumor resistance to immune responses |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
CN109313200B (en) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | Bioanalytical methods for characterizing site-specific antibody-drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (en) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | Pyrrolobenzodiazepine prodrug and its antibody conjugate |
JP7050770B2 (en) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Method for preparing antibody drug conjugate |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
KR20200032243A (en) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | Pyrrolobenzodiazepine-antibody conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3612537T (en) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (en) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Dosage regimes for the administration of an anti-cd19 adc |
DK3668874T3 (en) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
RU2020113749A (en) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | ANALOGUES OF THAILANSTATIN |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
IL296050A (en) | 2018-08-01 | 2022-10-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
TW202037381A (en) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | Conjugated chemical inducers of degradation and methods of use |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
CN114848822A (en) * | 2022-06-01 | 2022-08-05 | 合肥工业大学 | Application of GPR31 inhibitor in preparation of drugs for preventing and treating vascular calcification |
WO2024044659A1 (en) * | 2022-08-24 | 2024-02-29 | Tectonic Therapeutic, Inc. | Constitutively active g protein-coupled receptor compositions and methods of use thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2180529T3 (en) | 1990-02-26 | 2003-02-16 | Univ Leland Stanford Junior | IDENTIFICATION AND EXPRESSION OF DNA SEQUENCES OF AN INSECT STEROID RECEIVER. |
EP0668930B1 (en) | 1991-10-01 | 2002-12-18 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A method of identifying ligands and antagonists of ligands |
JPH07509694A (en) * | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | Mutated steroid hormone receptors, their uses and molecular switches for gene therapy |
CA2145182C (en) | 1992-09-25 | 2001-09-18 | Jonathan A. Bard | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
EP0612845A3 (en) | 1993-02-26 | 1994-09-21 | American Cyanamid Co | Purified opioid receptor. |
WO1995013373A1 (en) | 1993-11-10 | 1995-05-18 | Arch Development Corporation | Ubiquitous nuclear receptor: compositions and methods |
WO1995018380A1 (en) * | 1993-12-30 | 1995-07-06 | The Salk Institute For Biological Studies | Novel uses for gal4-receptor constructs |
US5573944A (en) | 1994-07-22 | 1996-11-12 | President And Fellows Of Harvard College | Yeast cell expressing heterologous receptor kinase |
CA2195768A1 (en) | 1994-08-11 | 1996-02-22 | Shuji Hinuma | G protein coupled receptor protein, production, and use thereof |
CA2135253A1 (en) | 1994-11-07 | 1996-05-08 | Michael Dennis | Compound screening based on a window of chemical-messenger-independent activity |
AU714642B2 (en) * | 1995-06-06 | 2000-01-06 | Human Genome Sciences, Inc. | G-protein receptor HTNAD29 |
WO1997011159A1 (en) | 1995-09-20 | 1997-03-27 | Molecular Geriatrics Corporation | Yeast receptor and g-protein fusion protein |
FR2742033B1 (en) * | 1995-12-08 | 1998-01-16 | Achart Jacques | APPARATUS FOR OPENING SHELLS OF BIVALVE MOLLUSCS |
WO1997021731A1 (en) | 1995-12-11 | 1997-06-19 | New England Medical Center Hospitals, Inc. | Assay for and uses of peptide hormone receptor ligands |
US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
US5932779A (en) * | 1996-06-10 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
US6399326B1 (en) | 1996-07-02 | 2002-06-04 | President And Fellows Of Harvard College | Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase |
US6159705A (en) * | 1996-09-24 | 2000-12-12 | Cadus Pharmaceutical Corporation | Recombinant yeast cells for identifying receptor effectors |
EP0960125A4 (en) | 1996-12-27 | 2002-09-25 | Merck & Co Inc | GALANIN RECEPTOR GalR2 AND NUCLEOTIDES ENCODING SAME |
US6403305B1 (en) | 1997-02-06 | 2002-06-11 | Cornell Research Foundation, Inc. | Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor |
US6255089B1 (en) | 1997-02-27 | 2001-07-03 | Albany Medical College | Constitutively activated serotonin receptors |
US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
IL130880A (en) | 1997-04-14 | 2004-03-28 | Arena Pharm Inc | Method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
US5891720A (en) | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
EP0878542A3 (en) | 1997-04-22 | 2000-04-19 | Smithkline Beecham Corporation | cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor |
EP1007563A4 (en) | 1997-06-12 | 2003-04-16 | Smithkline Beecham Corp | Hm74a receptor |
US5955308A (en) | 1997-06-18 | 1999-09-21 | Smithkline Beecham Corporation | cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor |
US6222029B1 (en) | 1997-08-01 | 2001-04-24 | Genset | 5′ ESTs for secreted proteins expressed in brain |
EP1029916B1 (en) | 1997-11-11 | 2007-05-23 | Ono Pharmaceutical Co., Ltd. | Human lysophosphatidic acid receptor and use thereof |
SE9704836D0 (en) | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
ES2332025T3 (en) | 1998-03-26 | 2010-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | NEW RECEPTORS OF PROTEIN COUPLED MAMMALS THAT HAVE EXTRACELLULAR REPETITION REGIONS RICH IN LEUCINA. |
MXPA00010060A (en) | 1998-04-14 | 2004-04-23 | Arena Pharm Inc | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof. |
WO2000006597A2 (en) * | 1998-07-31 | 2000-02-10 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated g protein-coupled orphan receptors |
AU5449099A (en) | 1998-09-03 | 2000-03-27 | Asahi Kasei Kabushiki Kaisha | Novel receptor protein and method for diagnosing inflammatory diseases by using the same |
US20030229216A1 (en) * | 1998-10-13 | 2003-12-11 | Ruoping Chen | Constitutively activated human G protein coupled receptors |
CA2348688A1 (en) | 1998-10-13 | 2000-04-20 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human g protein-coupled receptors |
CA2371821A1 (en) | 1999-02-19 | 2000-08-24 | Takeda Chemical Industries, Ltd. | Novel g protein-coupled receptor protein and dna thereof |
JP2003508026A (en) | 1999-07-15 | 2003-03-04 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Human G-protein coupled receptor |
WO2001007606A1 (en) | 1999-07-27 | 2001-02-01 | Smithkline Beecham Plc | Axor21, a g-protein coupled receptor |
CA2381979A1 (en) | 1999-08-17 | 2001-02-22 | Klaus Ducker | Pgpcr-3 polypeptides and dna sequences thereof |
WO2001014577A1 (en) | 1999-08-24 | 2001-03-01 | Smithkline Beecham Corporation | Molecular cloning of a galanin like 7tm receptor (axor40) |
WO2001016159A1 (en) | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, theant |
GB9923889D0 (en) | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
GB9924951D0 (en) | 1999-10-21 | 1999-12-22 | Pfizer Ltd | Novel polypeptide |
AU1575601A (en) | 1999-10-27 | 2001-05-08 | Pharmacia & Upjohn Company | G protein-coupled receptors expressed in brain |
EP1242448A2 (en) | 1999-11-17 | 2002-09-25 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
-
1998
- 1998-10-13 US US09/170,496 patent/US6555339B1/en not_active Expired - Lifetime
-
1999
- 1999-10-12 EP EP99951991A patent/EP1121431B9/en not_active Expired - Lifetime
- 1999-10-12 CN CNB99812091XA patent/CN1329511C/en not_active Expired - Fee Related
- 1999-10-12 WO PCT/US1999/023938 patent/WO2000022129A1/en active Application Filing
- 1999-10-12 DK DK99951991T patent/DK1121431T5/en active
- 1999-10-12 JP JP2000576019A patent/JP4672866B2/en not_active Expired - Fee Related
- 1999-10-12 IL IL14196599A patent/IL141965A0/en active IP Right Grant
- 1999-10-12 ES ES99951991T patent/ES2163384T3/en not_active Expired - Lifetime
- 1999-10-12 AU AU64307/99A patent/AU769987B2/en not_active Ceased
- 1999-10-12 DE DE69929993A patent/DE69929993D1/en not_active Expired - Lifetime
- 1999-10-12 DE DE69929993T patent/DE69929993T4/en not_active Expired - Lifetime
- 1999-10-12 WO PCT/US1999/023935 patent/WO2000021987A2/en active Search and Examination
- 1999-10-12 AT AT99951991T patent/ATE318311T1/en not_active IP Right Cessation
- 1999-10-12 NZ NZ510331A patent/NZ510331A/en not_active IP Right Cessation
- 1999-10-12 KR KR1020017004587A patent/KR100598752B1/en not_active IP Right Cessation
- 1999-10-12 CA CA002342314A patent/CA2342314A1/en not_active Abandoned
- 1999-10-12 JP JP2000575892A patent/JP4685241B2/en not_active Expired - Fee Related
- 1999-10-12 DE DE1121431T patent/DE1121431T1/en active Pending
-
2001
- 2001-03-12 IL IL141965A patent/IL141965A/en not_active IP Right Cessation
- 2001-12-20 HK HK01108940A patent/HK1038040A1/en not_active IP Right Cessation
-
2002
- 2002-09-20 US US10/251,385 patent/US7410777B2/en not_active Expired - Fee Related
-
2004
- 2004-07-08 AU AU2004203102A patent/AU2004203102B2/en not_active Ceased
-
2008
- 2008-01-16 AU AU2008200231A patent/AU2008200231A1/en not_active Abandoned
-
2011
- 2011-01-04 AU AU2011200016A patent/AU2011200016A1/en not_active Abandoned
- 2011-02-07 AU AU2011200511A patent/AU2011200511A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL141965A0 (en) | Non-endogenous, constitutively activated human g protein-coupled receptors | |
ES2243095T3 (en) | RECEPTORS COUPLED TO PROTEINA G HUMANOS HUERFANOS. | |
Jüppner et al. | The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34) | |
Krapivinsky et al. | The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K+-channel proteins | |
Howard et al. | Molecular cloning and characterization of a new receptor for galanin | |
US5883075A (en) | Cyclic endothelin antagonists | |
EP0849361B1 (en) | Novel ligands of the neuropeptide receptor HFGAN72 | |
AU1769601A (en) | Endogenous and non-endogenous versions of human G protein-coupled receptors | |
PT1012274E (en) | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) | |
EP1007563A1 (en) | Hm74a receptor | |
Blomenröhr et al. | Differences in structure–function relations between nonmammalian and mammalian gonadotropin-releasing hormone receptors | |
Zhang et al. | Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues | |
ES2201061T3 (en) | DELTA OPIOID RECEIVER GENES. | |
EP0552417A1 (en) | Cyclic peptides and use thereof | |
Maiti et al. | GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors | |
Durek et al. | Melanocortin 1 receptor agonists based on a bivalent, bicyclic peptide framework | |
CA2330251A1 (en) | Cloning and identification of the motilin receptor | |
DK0692026T3 (en) | A human T cell receptor from the G protein-coupled receptor family | |
Koshimizu et al. | Truncation of the receptor carboxyl terminus impairs membrane signaling but not ligand binding of human ETB endothelin receptor | |
Suva et al. | Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor | |
US7816492B2 (en) | Human G protein-coupled receptors | |
US20130089549A1 (en) | B cell activating factor antagonist and preparation method and use thereof | |
Langer et al. | Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists | |
Chhajlani | Characterization of a putative α-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding | |
Liu et al. | Cryo-EM structure of monomeric CXCL12-bound CXCR4 in active state |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |